This site is intended for healthcare professionals
Journals
  • Home
  • /
  • Journals
  • /
  • Psoriasis
  • /
  • Interleukin-17 inhibitors. A new era in treatment ...
Journal

Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases

Read time: 1 mins
Published:1st Aug 2016
Author: Wasilewska A, Winiarska M, Olszewska M, Rudnicka L.
Availability: Free full text
Ref.:Postepy Dermatol Alergol. 2016 Aug;33(4):247-52.
DOI:10.5114/ada.2016.61599
Interleukin-17 inhibitors. A new era in treatment of psoriasis and other skin diseases


Psoriasis is a chronic skin disease caused by the excessive secretion of inflammatory cytokines. Available therapeutic options include biologic drugs such as tumor necrosis factor alpha inhibitors and interleukin 12/23 (IL-12/23) inhibitors. The recent discovery of IL-17, which contributes to development of psoriasis, opened new possibilities for further treatment modalities. Currently, one anti-IL17 biological agent is approved for the treatment - a fully human monoclonal antibody that targets IL-17A (secukinumab). Further clinical trials, including a humanized IgG4 specific for IL-17 (ixekizumab) and a fully human antibody that targets the IL-17 receptor A (brodalumab).


Read abstract on library site    Access full article